Novalis Biotechnology Incubation
VC Fund
Gent, Belgium
Novalis Biotechnology Incubation is a VC fund in Gent focused on Health Care and Biotechnology. Novalis Biotech Incubation seeds biotechnology and life sciences-related companies. We focus on early-stage start-ups and support their evolution by providing funding, sharing our professional and academic connections, and help to shape the business strategy in order to create value for all stakeholders.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 63%
- Fund size:
- $30M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Novalis Biotechnology Incubation invests in
Stages Novalis Biotechnology Incubation invests in
Countries Novalis Biotechnology Incubation invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Health Care 6 (38%)
- Biotechnology 5 (31%)
- Biopharma 3 (19%)
- Medical 2 (13%)
- Genetics 2 (13%)
Stage
- Seed 6 (38%)
- Series A 4 (25%)
- Debt Financing 1 (6%)
Country
- France 2 (13%)
- Belgium 2 (13%)
- Sweden 1 (6%)
- Germany 1 (6%)
- Portugal 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Jan Berghe
Managing Director & Co-Founder
|
Managing Director & Co-Founder | Total investments: 1 | Find email | |
Jan Van den Berghe
Co-Founder
|
Co-Founder | Total investments: 3 | Find email | |
Kjell Mortier
Fund Manager
|
Fund Manager | Total investments: 2 | Find email | |
Wim van Criekinge
Co-Founder & Managing Director
|
Co-Founder & Managing Director | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Alithea Genomics develops molecular biology tools and sequencing-based solutions for large-scale gene expression analysis. The company provides technologies that use RNA barcoding and multiplexing methods to enable the analysis of many RNA samples within a single sequencing experiment. Its products support workflows for RNA sequencing, includinglibrary preparation methods designed for transcriptome profiling and gene expression studies. Alithea Genomics also offers reagents, protocols, and software tools that assist researchers in processing sequencing data and interpreting gene expression results. These technologies are used in academic and industry research settings to study biological processes, disease mechanisms, and cellular responses through transcriptomic analysis. | $3.8M / Seed / Mar 04, 2026 | ||
| Altavo operates as a medical device startup. Altavo harness the power of machine learning and state-of-the-art sensor technology to improve the lives of people who have lost their voice. | $3.5M / Series A / Jan 22, 2026 | ||
| Modality.ai is an AI-powered platform that detects health conditions using conversational AI. Through dialogue and video, Modality.AI interacts conversationally with the patient to provide health assessment anywhere, anytime. Its system analyzes multimodal data which allows continuous screening and assessing of patients’ health. | $570.5K / Seed / Oct 07, 2024 | ||
| Alithea Genomics develops molecular biology tools and sequencing-based solutions for large-scale gene expression analysis. The company provides technologies that use RNA barcoding and multiplexing methods to enable the analysis of many RNA samples within a single sequencing experiment. Its products support workflows for RNA sequencing, includinglibrary preparation methods designed for transcriptome profiling and gene expression studies. Alithea Genomics also offers reagents, protocols, and software tools that assist researchers in processing sequencing data and interpreting gene expression results. These technologies are used in academic and industry research settings to study biological processes, disease mechanisms, and cellular responses through transcriptomic analysis. | $3.2M / Seed / Mar 14, 2024 | ||
| Altavo operates as a medical device startup. Altavo harness the power of machine learning and state-of-the-art sensor technology to improve the lives of people who have lost their voice. | $5.4M / Series A / Feb 20, 2024 | ||
| Rarity Bioscience provides multiplex assays for detecting nucleic acid sequences in biological samples like liquid biopsies. | $536.5K / Seed / Feb 06, 2023 | ||
| C-mo is the solution providing a complete assessment of cough, adressing key use-cases across the patient management lifecycle. | $760.2K / Seed / Jan 31, 2023 | ||
| Enzyre is a developer of diagnostic technology. | $11.8M / Series A / Nov 02, 2022 | ||
| Modality.ai is an AI-powered platform that detects health conditions using conversational AI. Through dialogue and video, Modality.AI interacts conversationally with the patient to provide health assessment anywhere, anytime. Its system analyzes multimodal data which allows continuous screening and assessing of patients’ health. | $1.1M / Seed / Oct 07, 2022 | ||
| Carroucell is the microcarrier supplier for cell culture in bioreactor. | $1.5M / Series A / Sep 07, 2022 | ||
| See all 16 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Novalis Biotechnology Incubation invest in?
Novalis Biotechnology Incubation invests primarily in Health Care, Biotechnology and Biopharma startups, most often at Seed and Series A stage. Most of the 16 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Novalis Biotechnology Incubation?
Public channels for Novalis Biotechnology Incubation include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Novalis Biotechnology Incubation?
The team at Novalis Biotechnology Incubation includes Jan Berghe (Managing Director & Co-Founder), Jan Van den Berghe (Co-Founder) and Kjell Mortier (Fund Manager). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
